K562 Cells

Download PDF

Recent Publications on K562 Cells:
Inhibition of the Signal Transducer and Activator of Transcription-3 (STAT3) Signaling Pathway by 4-Oxo-1-Phenyl-1,4-Dihydroquinoline-3-Carboxylic Acid Esters. The JAK-STAT3 pathway regulates genes that are important in cell...	27th June, 2008	Oncology and Chemical and Screening Sciences, Wyeth Research, 401 North	J Med Chem. 2008 Jun 25;. DOI Direct Link
Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells. Delta-like-1 (Dlk1, also Pref-1), a transmembrane and secreted protein, is...	26th June, 2008	Leukemia Research Division, Jiangsu Institute of Hematology, Key	Int J Mol Med. 2008 Jul;22(1):61-8.
Differential expression of Wnt13 isoforms during leukemic cell differentiation. Wnt proteins control cell fate and differentiation during development....	26th June, 2008	Graduate Center for Nutritional Sciences, University of Kentucky,	Oncol Rep. 2008 Jul;20(1):195-201.
Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function. BACKGROUND: Interleukin (IL)-15-activated natural killer (NK) cells may...	25th June, 2008	Division of Allergy and Immunology, Department of Pediatrics, Chang Gung	Cytotherapy. 2008;10(4):397-405. DOI Direct Link
Changes of differentiation and proliferation in k562 cells with various levels of knockdown of cationic amino acid transporter 1. We recently showed that arginine transport via cationic amino acid...	25th June, 2008	Department of Membrane Transport and Pharmacokinetics, Faculty of	Drug Metab Pharmacokinet. 2008;23(3):181-7.
→View more research publications.

BioNews Results for K562 Cells:
Securin is required for chromosomal stability in human cells	PharmCast:  Apr 24 2008 12:13PM Matching: k562 cells

K562 Cells Clinical Trials:
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor	Glioma Intervention: Biological: GM-K562 Vaccination
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma	Follicular Lymphoma
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination	Chronic Lymphocytic Leukemia
Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer	Colorectal Cancer;   Metastatic Cancer
Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	Leukemia Interventions: Drug: GM-K562 cell vaccine;   Drug: recombinant interferon alfa;   Drug: sargramostim
→View more trials.

K562 Cells Patents:
US Patent No.	Title
7297759	Peptides for increasing transfection efficiency
7335351	Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
7338660	Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
7338774	Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same
7341721	.beta..sub.2-microglobulin (.beta..sub.2m) and anti-.beta..sub.2m binding agents as anti-cancer therapeutics
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for K562 Cells scientists - we have details of around 640 individuals working on K562 Cells .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.